Category Archives: Stem Cell Clinic


Adapting ideas from quantum physics to calculate alternative interventions for infection and cancer – Science Codex

CLEVELAND - Published in Nature Physics, findings from a new study co-led by Cleveland Clinic and Case Western Reserve University teams show for the first time how ideas from quantum physics can help develop novel drug interventions for bacterial infections and cancer.

The research team demonstrated that principles of quantum control, a field of quantum physics used in computing applications, can be translated and applied to biological problems. They constructed a mathematical algorithm that can be used to design and speed-up specific interventions to prevent or overturn drug resistance.

Typically cells in the presence of drugs evolve according to Darwinian natural selection: mutants that are resistant to the drug can outcompete their susceptible neighbors, dominating the population. Counterintuitively, one can also co-opt this process to achieve the opposite result, ultimately defeating drug resistance. For example, a mutation that causes resistance to one drug may cause extreme susceptibility to another, a phenomenon known as collateral sensitivity.

"If that mutant is initially only a small fraction of the population, we can use the first drug to encourage its dominance, and then apply the second drug to rapidly wipe out the infection," said physician-scientist Jacob Scott, MD, DPhil, a practicing radiation oncologist at Cleveland Clinic and co-senior author on the study, referencing findings from a study his group published earlier this year. "But we also know that the first stage can be slow: mutations occur at random times, and waiting long enough until the mutant fully takes over could compromise treatment effectiveness and patient outcomes. The time it takes to ensure these interventions are successful has been a significant limitation to adopting evolutionary medicine into clinical practice."

Speeding up this process is where quantum physics can provide inspiration. "The randomness of mutations in evolution has intriguing mathematical parallels to the randomness of quantum phenomena," according to Prof. Michael Hinczewski, a theoretical biophysicist at Case Western Reserve University and co-senior author. "This randomness makes it challenging to reliably and quickly drive a quantum system from one state to another. Solving this driving problem is an essential ingredient in certain kinds of quantum computing. Our new study exploits these parallels, translating a particular quantum technique known as counterdiabatic driving into the language of evolutionary biology."

"Imagine trying to get a system to follow a desired path from an initial to a final state over a short time--whether this path is a sequence of quantum states or varying proportions of mutants in an evolving population," said Prof. Hinczewski. "Counterdiabatic driving is a form of dynamic correction, providing just enough external intervention to keep the system on the path at every instant no matter how fast the protocol."

The researchers created a mathematical algorithm to calculate this intervention in evolutionary medicine applications. The algorithm's output is a prescription for dynamically altering the drug dosages or types to stay on the target path. The team demonstrated their technique by using it to manipulate evolution in simulations of living cells. These simulations were based on experimental data from an earlier study on a set of mutants showing varying degrees of resistance to anti-malarial drugs.

Counterdiabatic driving changed the proportion of mutants, affecting the population's overall drug sensitivity, faster and with better control than could be expected using current experimental methods in evolutionary medicine.

Given the team's promising findings, the next phase of their research will be to conduct direct experimental testing of the approach. As the first example of counterdiabatic driving in a biological context, the researchers are hopeful that their work could provide a foundation for a novel area of study: quantum-inspired biological control. The researchers plan to apply these ideas to other biological systems that share similarities with evolution, such as stem cell development and ecology.

Continued here:
Adapting ideas from quantum physics to calculate alternative interventions for infection and cancer - Science Codex

Global Degenerative Disc Disease Therapeutics Market Checkout the Unpredictable Future: Industry Applications, Competitors growth prospects, Industry…

Reportspedia published a new report, titled, Degenerative Disc Disease Therapeutics Market. GlobalDegenerative Disc Disease Therapeutics MarketPast, Present & Forecast Research 2020-2027 presents all-inclusive analysis & fundamental insights segmented by top companies, product type, geographical regions, applications & end-users. This brief breakdown provides 360-degree & complete Degenerative Disc Disease Therapeutics overview stating the opportunities, developmental factors, constraints & risks analysis. The forecast industry situations are presented based on past & present Smith Machines industry situations & growth rate.

Get Free Sample Copy:

https://www.reportspedia.com/report/others/2015-2027-global-degenerative-disc-disease-therapeutics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/60614#request_sample

Degenerative Disc Disease Therapeutics Market research report offers details about Industry Chain structure, Market Competition, Market Size, and Share, SWOT Analysis, Technology, Cost, Consumer Preference, Development and Trends, Regional Forecast, Company and Profile, and Product and Service.

LIST OF KEY COMPANIES PROFILED:

Samumed LLC DiscGenics Inc U.S. Stem Cell Inc BioRestorative Therapies Inc Biopharm GmbH AnGes Inc Bone Therapeutics SA Kolon TissueGene Inc Mesoblast Yuhan Corp Osiris Therapeutics Inc

This analysis includes a detailed share analysis of the key players. It also unveils the growth of the Degenerative Disc Disease Therapeutics Market participants along with their current statuses and key developments. The growth strategies employed by these players are also assessed in the report and are prognosticated to facilitate the study of the competitive landscape of the global Degenerative Disc Disease Therapeutics Market.

Geographically, this Research report focuses on market share, and growth opportunities in key regions such as United States, Europe, China, Japan, Southeast Asia, and India.

Ask For Discount:

https://www.reportspedia.com/discount_inquiry/discount/60614

Degenerative Disc Disease Therapeutics Market Segment by Type:

ALLOB AMG-0101 BRTX-100 OTICR-01 Others

Degenerative Disc Disease Therapeutics Market Segment by Application:

Clinic Hospital Homecare

The report objectives to provide an additional illustration of the latest scenario and COVID-19 impact on the overall industry

Inquire Before Buying:

https://www.reportspedia.com/report/others/2015-2027-global-degenerative-disc-disease-therapeutics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/60614#inquiry_before_buying

The Degenerative Disc Disease Therapeutics report provides insights in the following areas:

Table of Content:

Get Full Table of Content:

https://www.reportspedia.com/report/others/2015-2027-global-degenerative-disc-disease-therapeutics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/60614#table_of_contents

Why Reportspedia:

See the original post here:
Global Degenerative Disc Disease Therapeutics Market Checkout the Unpredictable Future: Industry Applications, Competitors growth prospects, Industry...

What voters need to know about Californias ballot propositions – OCRegister

Lets make some new rules for California gig workers!

Lets get back to the old rules when it comes to using race and ethnicity to admit or reject students at California universities!

Lets tweak the living heck out of the current rules that define the mother of all California tax laws, the 1978 version of Prop 13!

These are just a few of the dozen proposals that California voters will approve or reject in the Nov. 3 general election. Others would lower the voting age by a few months in primary elections, expand consumer privacy protection, change cash bail and give cities more clout regarding rent control, among other things.

Its a lot to consider. And given that mail-in ballots go out in early October, it might be time to look hard at what each proposition is about.

Heres a primer:

Vote yes for this and state taxpayers will be on the hook for $5.5 billion in bonds aimed at reviving the California Institute for Regenerative Medicine (CIRM), a program created in 2004 to boost stem cell research.

SCNG editorial boards endorsement on Proposition 14

A vote against it would save money, but it might kill CIRM. The 16-year-old program ran out of its initial funding last year and it hasnt taken on new research since last summer, according to the state.

Stem cells, if youre wondering, are used in medical research on everything from nerve disorders and blindness to tooth decay.

Prop. 14 would create some rules for how CIRM spends money going forward. And at least $1.5 billion would be used for research on age-related issues such as Alzheimers, Parkinsons, and dementia, among other things.

Supporters say keeping CIRM alive could be key to future medical breakthroughs.

Opponents note that federal limits on spending for stem-cell research the reason why California voters were asked to fund CIRM in the first place no longer exist.

A yes vote here would represent a big change in California, essentially creating two distinct tracks (split roll) one for most commercial buildings and another for residential dwellings in our famed Proposition 13 property tax code.

SCNG editorial boards endorsement on Proposition 15

Under Prop. 15, the tax rate on most commercial and industrial properties would be based on the buildings market value, not its purchase price. Exceptions would be made for buildings used in agriculture and for buildings owned by individuals or companies with less than $3 million in other assets. Overall, the state estimates it would generate up to $12.5 billion a year in new taxes from the owners of commercial properties.

A no vote would leave Californias Prop. 13 tax rules intact. All structures in California commercial, industrial, residential would continue to be taxed as they are now, with annual tax hikes jumping no more than the rate of inflation or 2%, whichever is lower.

Supporters say Prop. 15 would close a loophole that often benefits big businesses at the expense of small businesses, and that the money raised would help offset revenue losses expected as a result of the coronavirus pandemic.

Opponents say it will hurt job creation and make California a less attractive place to do business. Others argue its effectively a tax hike at a time when businesses are already struggling.

A yes vote on Prop. 16 would make it legal to consider race and gender, among other things, as potentially favorable factors when it comes to making decisions about public employment, public education and public contracting.

Technically, Prop. 16 is a constitutional amendment to repeal Prop. 209, a 1996 law approved by voters that ended the use of affirmative action in California.

Legally, Prop. 16 would reinstate the federal version of affirmative action, which allows for race-based and sex-based preferences in the interest of promoting diversity as long as quotas and other strict mandates arent part of any acceptance formula.

Supporters argue that Prop. 16 would be a step to helping undo the results of long-standing race and gender discrimination that have been key to economic and social inequality. They note that most states already follow federal guidelines on affirmative action.

Opponents counter that by saying any law that allows preferences essentially legalizes racism and sexism. Some also argue that Asian students who currently qualify for University of California schools at roughly twice the rate of other race and ethnic groups could be unfairly affected by Prop 16.

A yes vote for Prop. 17 would make it legal for people to vote while on parole for a felony conviction.

SCNG editorial boards endorsement on Propositions 17 and 18

Right now, in California, felons cant vote until after theyve served both their prison sentence and any parole. And, just so were clear, Prop. 17 does not propose letting felons vote while in prison.

Supporters say parolees are in the process of rejoining public life and that voting, much like working and paying taxes, is part of being a member of your community.

Opponents say voting is a right that should not be restored until a felon has completed all of his or her punishment, including parole.

A yes vote would make it legal for people who will turn 18 in time for the general election to vote, even while still 17, in that years primary.

SCNG editorial boards endorsement on Propositions 17 and 18

Supporters say the move would boost the number of engaged, informed voters in any election cycle.

Opponents note that people under 18 are children. They also argue that because almost all 17-year-olds still live with their parents their votes might be unfairly influenced.

This complicated, grab bag of a proposal would allow older homeowners (ages 55 and up), as well as disabled people and people whove lost properties in a natural disaster, to take some of their property tax base with them when they sell a home and buy a new one.

SCNG editorial boards endorsement on Proposition 19

It also would make it harder to keep a low property tax rate while transferring properties between generations.

And, finally, most of the new money generated by these changes would be used to help pay for firefighting.

The details matter. Specifically, Prop. 19 would:

Bump up from one to three the number of times an older individual can move while keeping their original property tax rate.

Limit a familys ability to pass on a low tax rate to properties used as principal residences, and limit the low tax rate to the first $1 million in equity. Right now, a parent or grandparent can bestow their low tax rate while passing on a rental home or vacation property. That feature would be eliminated under Prop. 19.

Supporters say the law will make it easier for older people to move. And supporters in the real estate industry like the idea that it could promote buying and selling of homes.

Opponents say Prop. 19 will result in less money for schools and other public entities funded by property taxes in California. A similar idea without the firefighting fund failed in 2018. It also was backed by the home-selling industry.

A yes vote for Prop. 20 would add to the states list of wobbler crimes, violations that currently are misdemeanors but, under this proposal, could be charged as felonies in some circumstances. Were talking about crimes like organized petty theft, credit card scams and stealing a firearm, among others.

Prop. 20 also would create stiffer penalties for people who violate terms of their parole three times and make it tougher for people convicted of certain crimes including domestic violence to be considered for early parole. And, finally, Prop. 20 would require that DNA samples be taken from people convicted of some misdemeanors.

Supporters say some crimes now considered minor have a serious effect on victims and, because of that, warrant tougher penalties.

Opponents argue that harsh sentencing guidelines havent prevented crime and that an opposite trend in recent years has made California safer.

A yes vote on Prop. 21 would let cities write new rent control laws for older housing (15 years and older) or expand any rent control rules they already have on the books.

SCNG editorial boards endorsement on Proposition 21

The proposal carves out an exception for single-family homes owned by landlords with no more than two properties. And, while Prop. 21 would wipe out the Costa-Hawkins Rental Housing Act (Costa-Hawkins) of 1995, it would not change the 7% rent hike limit set by state lawmakers last year.

Supporters say this could make a dent in homelessness and housing unaffordability, two problems that have reached crisis levels in California.

Opponents say rent control doesnt work as intended and that other rules including limits on building restrictions would better address the problems targeted by Prop. 21.

Do you work for an app like Lyft or Uber? If so, a yes vote on Prop. 22 would make you an independent contractor, same as you were before the passage of AB 5, which took effect last September.

SCNG editorial boards endorsement on Proposition 22

Under Prop. 22, rideshare and delivery companies that depend on armies of gig workers, would not have to pay standard wage and hour restrictions, though they would have to provide an earnings floor and some money to purchase health insurance, among other things.

A no vote on Prop. 22 means existing law including AB 5 will apply to all employers.

Its important to note that Prop. 22 is about people who use their own cars and cell phones as keys to their trade. Independent musicians, writers and others who work independently but dont use tech platforms as a tool would remain covered by controversial AB 5.

Supporters say Prop. 22 will keep rideshare and delivery services inexpensive.

Opponents say the employers who depend on gig workers have abused that relationship and are simply refusing to pay minimum wage, something all other businesses must do. Others also point out that Prop. 22 does nothing to address the problems created by AB 5, which has led to less work for some traditional independent contractors and financial problems for their employers.

A yes vote on Prop. 23 would mean at least one physician would have to be on site at an operating dialysis clinic. It also would require clinics to report on infections and get health department approval to close. And it would prohibit clinics from discriminating against patients based on how they pay for the clinics services.

SCNG editorial boards endorsement on Proposition 23

Supporters say the new rules would make it safer for kidney dialysis patients.

Opponents say the new rules would add burdensome costs.

A yes vote on Prop. 24 would expand and add to Californias two-year-old law on consumer data privacy and its reuse. Consumers could prohibit companies from sharing their personal information for any reason and shorten the period companies currently are given to fix the problem.

Prop. 24 also would create a Privacy Protection Agency to enforce the new rules.

Some other details in Prop. 24:

Companies would be limited when collecting data on any consumer younger than 16, and would need permission from a parent or guardianto collect data on consumers younger than 13.

Companies would have to correct any inaccurate information upon request.

Supporters say Prop. 24 adds teeth to the privacy law that California voters approved in 2018.

Opponents say Prop. 24 doesnt go far enough, and it would serve as a giveaway to the biggest social media companies.

Two years ago, state legislators passed a law (SB 10) to end cash bail in California. A yes vote on Prop. 25 would keep that law in place, replacing cash bail with a risk assessment system that would let people wait for trial at home based on a variety of factors.

A no vote on Prop. 25 would maintain the cash bail system, letting people stay or leave jail while awaiting trial based largely on their ability to pay.

Supporters argue that cash bail is, by definition, an unequal application of justice favoring people with money. They also note that Prop. 25 is a referendum sponsored by the cash bail industry and that its success would pave the way for other industries to simply spend their way around laws they dont like.

Opponents say the risk assessment system that would replace cash bail is biased and, because it uses computer modeling, is potentially inflexible.

Read the original:
What voters need to know about Californias ballot propositions - OCRegister

Diabetic patients may find ray of hope in stem cell treatment – The News International

Diabetic patients may find ray of hope in stem cell treatment

TOKYO: Diabetic patients may find a treatment after scientists developed a new technique that grows insulin-producing cells and can protect them from immune attack after they are transplanted.

In type-1 diabetes, the body turns on itself and attacks the so-called beta cells inside clusters in the pancreas called "islets".

These beta cells are responsible for gauging sugar levels in the blood and releasing insulin to keep them stable. Without them, diabetics must rely on insulin injections or pumps.

One treatment devised to end that reliance involves transplanting donor islets into diabetics, but the process is complicated by several obstacles, including a shortage of donors.

Islets also often fail to connect with blood supply, and even when they do, like other transplants, they can come under attack by the recipient's immune system, which views the cells as invaders.

As a result, patients have to take drugs that suppress their immune systems, protecting their transplant but potentially exposing the rest of their body to illness.

In a bid to overcome some of these challenges, a team looked to find another source for islets, by coaxing induced pluripotent stem cells (iPS) to produce what the team called HILOs, or human islet-like organoids.

These HILOs, when grown in a 3D environment mimicking the pancreas and then turbocharged with a "genetic switch", successfully produced insulin and were able to regulate blood glucose when transplanted into diabetic mice.

"In the past, this functionality was only achieved after a month-long maturation in a living animal," said Ronald Evans, director of the Gene Expression Lab at the Salk Institute for Biological Studies.

"This breakthrough allows for the production of functional HILOs which are active on the first day of transplantation, placing us closer to clinical applications," Evans, who led the study, told AFP.

Giving hope

Having found a potential way to solve the supply chain problem, the scientists then sought to tackle the issue of immune rejection.

They focused on something called PD-L1, a so-called checkpoint protein that is known to inhibit the body's immune response.

In cancer treatments, medication is sometimes used to block PD-L1, boosting the body's immune response to cancer cells.

The team effectively reversed that process, and induced the HILOs to express the protein in a bid to outwit the immune system.

"Normally, human cells placed in a mouse would be eliminated within a day or two," said Evans.

"We discovered a way to create an immune shield that makes human cells invisible to the immune system."

While HILOs transplanted into mice without the PD-L1 protection gradually stopped functioning, those induced to express the protein were shielded and continued to help diabetic mice regulate their blood glucose for more than 50 days.

Being able to grow insulin-producing cells and protect them from attack "brings us much closer to having a potential therapy for type-1 diabetic patients," Evans said.

Around 422 million people worldwide were living with diabetes by 2014, according to the World Health Organization, a figure that includes both type-1 and type-2 diabetes.

Islet transplantation is generally considered as a treatment for type-1 diabetics, whose disease is the result of an auto-immune response.

Evans cautioned that the research, already a decade in the making, was still years from being able to treat diabetes in humans.

"To advance HILOs into the clinic, we need to confirm that they work in other animal models, including primates, as well as do longer-term studies in mice," he said.

He hopes that human studies of the technique will be possible in two to five years.

"This is a hard-to-manage disease and insulin is not a cure," he added, noting that 1.6 million children and teenagers are living with type-1 diabetes in the United States alone.

"Good science is not just a discovery it can enrich the world and give hope to those who live with disease."

Read more:
Diabetic patients may find ray of hope in stem cell treatment - The News International

Animal Stem Cell Therapy Market with leading companies like ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and…

Stem cellsare being used to treat illness and heal injuries in pets. They are injected into the body to repair muscles, joints, and ligaments that have been damaged by arthritis or injury. Some cancers are treated withstem cellstaken from the pets own bone marrow.

The report, titled Animal Stem Cell Therapy Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

Sample Report with Latest Industry Trends @:

https://www.qyreports.com/request-sample/?report-id=51946

Top Key Companies Players Analyzed in this Report are:

Magellan Stem Cells, ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital, Clinic Frisco, CO, Medivet Biologics LLC

The scope of the Animal Stem Cell Therapy Market report is as follows the report provides information on growth segments and opportunities for investment and Benchmark performance against key competitors. Geographically, the global mobile application market has been segmented into four regions such as North America, Europe, Asia Pacific and the rest of the world.

This report gives an in depth and broad understanding of Animal Stem Cell Therapy Market. With accurate data covering all key features of the prevailing market, this report offers prevailing data of leading companies. Appreciative of the market state by amenability of accurate historical data regarding each and every sector for the forecast period is mentioned. Driving forces, restraints and opportunities are given to help give an improved picture of this market investment for the forecast period.

Get Reasonable Discount on this Premium Report @:

https://www.qyreports.com/ask-for-discount/?report-id=51946

Finally, all aspects of the Global Animal Stem Cell Therapy Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

Following are the List of Chapter Covers in the Animal Stem Cell Therapy Market:

Animal Stem Cell Therapy Market Overview

Global Economic Impact on Industry

Global Market Competition by Manufacturers

Global Market Analysis by Application

Marketing Strategy Analysis, Distributors/Traders

Market Effect Factors Analysis

Global Animal Stem Cell Therapy Market Forecast

For More Information:

https://www.qyreports.com/enquiry-before-buying/?report-id=51946

*If you need anything more than these then let us know and we will prepare the report according to your requirement.

About QYReports:

We at QYReports, a leading market research report publisher cater to more than 4,000 prestigious clients worldwide meeting their customized research requirements in terms of market data size and its application. Our list of customers includes renowned Chinese companys multinational companies, SMEs and private equity firms. Our business study covers a market size of over 30 industries offering you accurate, in depth and reliable market insight, industry analysis and structure. Reports specialize in forecasts needed for investing in an and execution of a new project globally and in Chinese markets.

Contact Us:

Jones John

Contact number: +1-510-560-6005

204, Professional Center,

7950 NW 53rd Street, Miami, Florida 33166

[emailprotected]

http://www.qyreports.com

See the rest here:
Animal Stem Cell Therapy Market with leading companies like ANIMAL CELL THERAPIES, Abbott Animal Hospital, VETSTEM BIOPHARMA, Veterinary Hospital and...

Jocelyn McGlynn inspired people to help others – Chatham This Week

Jocelyn McGlynn (left) who died Aug. 15 after a battle with acute myelomonocytic leukemia, will be greatly missed by childhood friends Anastasia Maslak (centre) and Olivia Pomajba. The trio, from Chatham, attended elementary and high school together and were roommates while attending Western University in London. Handout/Postmedia Network

While leukemia claimed the life of aspiring doctor Jocelyn McGlynn, she left a legacy that will help save others because she inspired more than 2,000 people to join Canadas stem-cell registry.

The 23-year-old Chatham woman died Aug. 15 after a lengthy battle with the disease.

Diagnosed with acute myelomoncytic leukemia on Nov. 30, 2018, the Western University student and her family took up the cause of the ongoing need for stem-cell donations, not only to help McGlynn but many others in need of the life-saving procedure.

The McGlynn family was joined by many friends and family in organizing blood donor clinics where people could also join the stem-cell registry.

Olivia Pomajba and Anastasia Maslak, two of McGlynns closest friends and her roommates at Western, were part of that effort.

That was a huge gift to be able to tangibly do something instead of just sitting at home and being very sad, said Pomajba, who helped at blood donor clinics and a swab clinic at Western University in early 2019 that attracted a record 767 people.

She said people came out of the woodwork during the months they searched for a viable stem-cell match for McGlynn.

Pomajba was amazed that many people McGlynn had met in passing were all just struck by how lovely and kind she was to them, even briefly, and wanted to help.

That was a huge blessing for me to meet all these people that shes touched who all signed up to be stem cell donors, she said.

Pomajba said McGlynn helped inspire more than 2,000 people to join the stem-cell registry. A number of the newly registered donors turned out to be stem-cell matches for other patients, she added.

McGlynns friends were amazed by the grace she showed throughout the high of finding a perfect stem-cell match and undergoing a successful transplant in February 2019 to the lows of suffering two relapses.

Her No. 1 concern was other people. I dont think she wanted us to worry about her, so she put on a really brave face and smiled the whole time, Pomajba said.

Having concern for others is something McGlynns friends knew was part of her makeup.

Maslak said McGlynn had a talent for being able to cheer people up.

I remember there were so many times, whether it be in high school or when we were living together in university, where I would be just having rough day and she would put on this performance and would have me laughing so hard I was in tears, Maslak said.

Her signature thing was, whenever we would go anywhere, she would always be holding the door open, literally, for everyone who would pass by.

She said McGlynn would smile and have conversations with people and offer her well wishes.

It would just take forever to move down the hallway in high school because she was just always so kind and friendly, Maslak said.

McGlynn is also remembered by her roommates for decorating their university home for every holiday and special occasion, including Christmas and Thanksgiving but including Halloween.

We were probably to the point we were annoying our other roommates because there were decorations from multiple holidays up all the time, Pomajba said.

Shes woven into the fabric of everything weve ever done, like every holiday, every birthday, every milestone.

McGlynn was in her final year of the four-year medical science program at Western when the leukemia first struck.

She wrote her Medical College Admission Test the previous summer and achieved a score that qualified her for acceptance at every medical school in Ontario.

She was so excited about medicine, Pomajba said. She would have had a great beside manner and been so kind to people.

McGlynn was so keen on becoming a doctor, specifically a pediatrician, that she embraced the opportunity to learn while undergoing treatment for leukemia.

During a telephone interview in early January 2019, after having already spent a month in a London hospital, McGlynn she told the Chatham Daily News: Ive learned a lot about how important wording is, how important phrasing is. I think that will definitely help me.

She added: Everyone Ive met has been awesome. Im going to use the tools theyve shown me and hopefully implement that when I reach my goal.

McGlynn is the daughter of Peter and Jacquelyn McGlynn and a sister to Maxx and Zach.

Follow this link:
Jocelyn McGlynn inspired people to help others - Chatham This Week

Global Stem Cell and Primary Cell Culture Medium Market Report: Production, Revenue, Price Trend by Types & Market Analysis by Application -…

Stem Cells are a class of cells that have unlimited or immortal self-renewal ability, capable of producing at least one type of highly differentiated progeny cells. Primary Cells are cells that are cultured immediately after removal from the body. Stem Cell and Primary Cell Cultures are specialized systems, and as such developing and manufacturing media for these systems come with inherent complexities.

The global Stem Cell and Primary Cell Culture Medium market is valued at US$ xx million in 2020 is expected to reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2021-2026.

Access more details about this report at: https://www.themarketreports.com/report/global-stem-cell-and-primary-cell-culture-medium-market-research-report

(This is our latest offering and this report also analyzes the impact of COVID-19 on Stem Cell and Primary Cell Culture Medium market and updated by the current situation, especially the forecast)

The research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of production about the global market and also about each type from 2015 to 2026. This section mentions the volume of production by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

The major players in the market include Merck, STEMCELL Technologies, Irvinesci, Cell Applications, Inc, Biological Industries, Miltenyi Biotec, Swiss Medica Clinic, Promocell, Creative Biolabs, Lifeline Cell Technology, ScienCell Research Laboratories, Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCR Pharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix), etc.

Purchase this exclusive research report at: https://www.themarketreports.com/report/buy-now/1546660

Global Stem Cell and Primary Cell Culture Medium Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Stem Cell and Primary Cell Culture Medium market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Stem Cell and Primary Cell Culture Medium Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Inquire for more details / sample / customization about this report at: https://www.themarketreports.com/report/ask-your-query/1546660

Read this article:
Global Stem Cell and Primary Cell Culture Medium Market Report: Production, Revenue, Price Trend by Types & Market Analysis by Application -...

Hackensack University Medical Center Has the Best Cancer Center in New Jersey John Theurer Cancer Center recognized by U.S. News & World Report -…

Newswise HACKENSACK, N.J.,AUGUST 17, 2020 U.S. News & World Report has recognized John Theurer Cancer Center at Hackensack University Medical Center as the best cancer center in New Jersey. The recognition reflects the extraordinary strength of its comprehensive patient care, research and education programs.

In 2019, John Theurer Cancer Center became a member of the National Cancer Institute-approved Georgetown Lombardi Comprehensive Cancer Center Consortium, making the Cancer Center a member of one of just 16 cancer consortia based at the nation's most prestigious institutions. The NCI endorses such consortia to bring together accomplished institutionswith independently proven records of excellence to join forces in pursuit of the NCI's original mission: improving cancer outcomes through scientific discovery, reducing the impact of cancer on individuals and communities and diminishing cancer disparities, and developing the next generation of cancer scientists, clinicians and educators.

John Theurer Cancer Center is organized into 16 specialized divisions, each led by a recognized expert in the field. With a strong focus on clinical science and innovation, John Theurer Cancer Center investigators were directly involved in the development of more than 40 new anticancer agents approved by the U.S. Food and Drug Administration over the last three yearsparticularly for blood cancers such as leukemia, lymphoma, and multiple myeloma, as well as solid tumors through Phase I first-in-human clinical trials.

"Our multidisciplinary team cares for patients with cancers of every type and stage in a highly subspecialized environment," said Robert C. Garrett, FACHE, CEO, Hackensack Meridian Health. "Our commitment to cancer is reflective of our approach to everything we do: to provide the most advanced health care services based on the latest findings of medical research in a compassionate, culturally sensitive setting. It is an honor for us to be recognized as the top cancer center in our state."

"Our exceptional team is proud to be recognized as the top cancer program in New Jersey. The scope and depth of expertise, together with our focus on clinical science and innovation, are what make our Cancer Center a destination program, explained Andre Goy, M.D., M.S., chair and chief physician of John Theurer Cancer Center, Lymphoma Division chief, physician-in-chief of the Hackensack Meridian Health Oncology Care Transformation Service, and a renowned lymphoma expert who led the Cancer Center's participation in the pioneering ZUMA-2 study. "Understandably, every person who receives a diagnosis of cancer seeks the center with the most experience and the best innovation. This is why patients come to John Theurer Cancer Center. We take care of each patient in a compassionate and friendly environment, and that's what makes our patients smile.

A number of metrics support that successful track record:

This recognition as the state's best cancer center reflects the strength of our research, the dedication of our multidisciplinary team, and the expertise of our physicians," said Ihor Sawczuk, MD, FACS, Hackensack Meridian Health regional president, Northern Market and chief research officer. We are grateful to our patients who have trusted us with their care and who continually inspire us to provide the best possible experience.

For more information, please contact Katherine Emmanouilidis, Director, Communications & Public Relations, 551-996-3764.

About Hackensack Meridian Health Hackensack University Medical Center

Hackensack Meridian Health Hackensack University Medical Center, a 781-bed nonprofit teaching and research hospital located in Bergen County, NJ, is the largest provider of inpatient and outpatient services in the state. Founded in 1888 as the countys first hospital, it is now part of the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care, which is comprised of 35,000 team members and more than 7,000 physicians. Hackensack University Medical Center is ranked #2 in New Jersey and #59 in the country in U.S. News & World Reports 2019-20 Best Hospital rankings and is ranked high-performing in the U.S. in colon cancer surgery,lung cancersurgery,COPD, heart failure, heart bypass surgery, aortic valve surgery,abdominal aortic aneurysm repair, knee replacement and hip replacement. Out of 4,500 hospitals evaluated, Hackensack is one of only 57 that received a top rating in all nine procedures and conditions. Hackensack University Medical Center is one of only five major academic medical centers in the nation to receive Healthgrades Americas 50 Best Hospitals Award for five or more years in a row. Beckers Hospital Review recognized Hackensack University Medical Center as one of the 100 Great Hospitals in America 2018. The medical center is one of the top 25 green hospitals in the country according to Practice Greenhealth, and received 28 Gold Seals of Approval by The Joint Commission more than any other hospital in the country. It was the first hospital in New Jersey and second in the nation to become a Magnet recognized hospital for nursing excellence; receiving its sixth consecutive designation in 2019. Hackensack University Medical Center has created an entire campus of award-winning care, including: John Theurer Cancer Center, a consortium member of the NCI-designated Georgetown Lombardi Comprehensive Cancer Center; the Heart & Vascular Hospital; and the Sarkis and Siran Gabrellian Womens and Childrens Pavilion, which houses the Joseph M. Sanzari Childrens Hospital and Donna A. Sanzari Womens Hospital, which was designed with The Deirdre Imus Environmental Health Center and listed on the Green Guides list of Top 10 Green Hospitals in the U.S. Hackensack University Medical Center is the Hometown Hospital of the New York Giants and the New York Red Bulls and is Official Medical Services Provider to THE NORTHERN TRUST PGA Golf Tournament. It remains committed to its community through fundraising and community events especially the Tackle Kids Cancer Campaign providing much needed research at the Childrens Cancer Institute housed at the Joseph M. Sanzari Childrens Hospital. To learn more, visit http://www.HackensackUMC.org.

About John Theurer Cancer Center atHackensack University Medical Center

John Theurer Cancer Center at Hackensack University Medical Center is New Jerseys largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 16 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey.John Theurer Cancer Center is amember of the Georgetown Lombardi Comprehensive Cancer Center Consortium,one of just 16 NCI-approved cancer research consortiabased at the nations most prestigious institutions. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish John Theurer Cancer Center from other facilities.For additional information, please visitwww.jtcancercenter.org

ABOUTHACKENSACKMERIDIAN HEALTH

Hackensack Meridian Health is a leading not-for-profit health care organization that is the largest, most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care.

Hackensack Meridian Health comprises 17 hospitals from Bergen to Ocean counties, which includes three academic medical centers Hackensack University Medical Center in Hackensack, Jersey Shore University Medical Center in Neptune, JFK Medical Center in Edison; two childrens hospitals - Joseph M. Sanzari Childrens Hospital in Hackensack, K. Hovnanian Childrens Hospital in Neptune; nine community hospitals Bayshore Medical Center in Holmdel, Mountainside Medical Center in Montclair, Ocean Medical Center in Brick, Palisades Medical Center in North Bergen, Pascack Valley Medical Center in Westwood, Raritan Bay Medical Center in Old Bridge, Raritan Bay Medical Center in Perth Amboy, Riverview Medical Center in Red Bank, and Southern Ocean Medical Center in Manahawkin; a behavioral health hospital Carrier Clinic in Belle Mead; and two rehabilitation hospitals - JFK Johnson Rehabilitation Institute in Edison and Shore Rehabilitation Institute in Brick.

Additionally, the network has more than 500 patient care locations throughout the state which include ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, urgent care centers and physician practice locations. Hackensack Meridian Health has more than 36,000 team members, and 7,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The networks notable distinctions include having four of its hospitals are among the top hospitals in New Jersey for 2020-21, according toU.S. News & World Report. Additionally, the health system has more top-ranked hospitals than any system in New Jersey. Childrens Health is again ranked a top provider of pediatric health care in the United States and earned top 50 rankings in the annual U.S. News 2020-21 Best Childrens Hospitals report. Other honors include consistently achieving Magnet recognition for nursing excellence from the American Nurses Credentialing Center and being named to Beckers Healthcares 150 Top Places to Work in Healthcare/2019 list.

The Hackensack Meridian School of Medicine, the first private medical school in New Jersey in more than 50 years, welcomed its first class of students in 2018 to its On3 campus in Nutley and Clifton. The Hackensack Meridian Center for Discovery and Innovation (CDI), housed in a fully renovated state-of-the-art facility, seeks to translate current innovations in science to improve clinical outcomes for patients with cancer, infectious diseases and other life-threatening and disabling conditions.

Additionally, the network partnered with Memorial Sloan Kettering Cancer Center to find more cures for cancer faster while ensuring that patients have access to the highest quality, most individualized cancer care when and where they need it.

Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

To learn more, visit http://www.hackensackmeridianhealth.org.

See the article here:
Hackensack University Medical Center Has the Best Cancer Center in New Jersey John Theurer Cancer Center recognized by U.S. News & World Report -...

Novel CAR T-Cell Therapy Shows Promise in Advanced Hodgkin Lymphoma – Curetoday.com

Unlike other CAR T-cell therapies, clinical success was not associated with significant complications from therapy, said Dr. Jonathan Serody. This means this treatment should be available to patients in a clinic setting and would not require patients to be hospitalized, which is critical in our current environment.

Results from the parallel phase 1 and phase 2 studies also demonstrated that the CAR T-cell therapy was safe and did not produce any serious or severe side effects.

Researchers from the UNC Lineberger Comprehensive Cancer Center and Baylor College of Medicine administered anti-CD30 CAR T cells to 41 patients with relapsed or refractory Hodgkin lymphoma. All patients underwent lymphodepletion with bendamustine alone, bendamustine and fludarabine, or cyclophosphamide and fludarabine prior to the anti-CD30 CAR T-cell therapy.

Measuring safety was the primary goal of the two parallel studies.

The overall response rate, or the percentage of partial or complete responses to therapy, among 37 evaluable patients was 62%. Thirty-four of the patients received fludarabine-based lymphodepletion 17 of which received it with bendamustine, and the other half received it with cyclophosphamide. Two of these patients were considered to be complete response at infusion and maintained the response, so they were not included in final analysis.

The overall response rate among the remaining patients was 72%, with 59% of patients achieving a complete response. After a median follow-up of 533 days, researchers identified the one-year progression free survival rate to be 36% and the one-year overall survival rate to be 94%.

This is particularly exciting because the majority of these patients had lymphomas that had not responded well to other powerful new therapies, said senior study author Dr. Barbara Savoldo, professor in the Department of Microbiology and Immunology at the UNC School of Medicine, in a press release. Patients within the study had received a median of seven previous lines of therapy that included checkpoint inhibitors and autologous or allogeneic stem cell therapies, therapies known to be powerful but also tend to come with a host of side effects.

However, treatment with the anti-CD30 CART cells demonstrated a favorable safety profile. Although 10 patients developed cytokine release syndrome, all cases were considered minor.

Patients who received fludarabine-containing lymphodepletion were the only participants in the study to have a response to the anti-CD30 CAR T-cell therapy.

Although CD30 CAR T (cells) showed modest activity in (Hodgkin lymphoma) when infused without lymphodepletion, robust clinical responses were achieved when these cells were infused in hosts lymphodepleted with fludarabine-containing regimens, the authors wrote.

The activity of this new therapy is quite remarkable and while we need to confirm these findings in a larger study, this treatment potentially offers a new approach for patients who currently have very limited options to treat their cancer, said Dr. Jonathan Serody, director of the bone marrow transplant and cellular therapy program at UNC Lineberger Comprehensive Cancer Center, in the release. Additionally, unlike other CAR T-cell therapies, clinical success was not associated with significant complications from therapy. This means this treatment should be available to patients in a clinic setting and would not require patients to be hospitalized, which is critical in our current environment.

View post:
Novel CAR T-Cell Therapy Shows Promise in Advanced Hodgkin Lymphoma - Curetoday.com

Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors |…

Details Category: Proteins and Peptides Published on Thursday, 13 August 2020 10:22 Hits: 282

HARRISON, NY, USA I August 12, 2020 I Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult-to-treat oncology indications, today announced dose administration for the first patient in a Phase 1/2, open-label, dose escalation and expansion study of single agent ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors who are not eligible for other therapies or have progressed on prior therapies.

"The initiation of this study represents a significant milestone for Sapience, as it marks the first program from our portfolio of peptide therapies to enter the clinic," said Alice Bexon, M.D., Chief Medical Officer of Sapience Therapeutics. "The ST101 program highlights Sapience's therapeutic approach of using peptides to target intracellular protein-protein interactions, which are often referred to as 'Undruggable Targets'. Through this study, we anticipate generating a wealth of clinical data to guide our future development plans for this first-in-class antagonist of C/EBP."

Nehal Lakhani, M.D., Ph.D., Director of Clinical Research at START Midwest (South Texas Accelerated Research), and a clinical investigator on the study added, "We are eager to explore the profile of ST101 and to investigate the role of C/EBP inhibition for the treatment of advanced solid tumors. We are always looking for opportunities to accelerate the development of new treatments to improve patients' lives and give them hope against cancer, and ST101 holds that potential."

The Phase 1/2 trial will enroll patients at several leading clinical centers in the US and UK. The trial will start with a dose escalation phase to assess the safety and tolerability of ST101, followed by an expansion phase to evaluate preliminary efficacy in patients with glioblastoma, locally advanced/metastatic breast cancer, castration-resistant prostate cancer and melanoma. Please refer to http://www.clinicaltrials.gov for additional information (NCT 04478279).

About ST101

ST101 is a peptide antagonist of the transcription factor C/EBP, which is typically expressed and active in stem cells or early progenitor cells but not in most mature or differentiated cells. Certain cancers activate C/EBP, which results in the expression of genes with roles in cell proliferation, differentiation, and the cell cycle. Disruption of this transcription factor with ST101 results in targeted killing of cancer cells, as normal cells do not rely on C/EBP driven transcription for survival.

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein-protein interactions, Sapience's molecules hold potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit http://www.sapiencetherapeutics.com.

SOURCE: Sapience Therapeutics

Continued here:
Sapience Therapeutics Announces First Patient Dosed with ST101 in Phase 1/2 Study in Patients with Advanced Unresectable and Metastatic Solid Tumors |...